Amdizalisib clinical trials
Also written HMPL-689.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2016
How each study uses amdizalisib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- HMPL-689
- 5
Studies by the year they started
5 studies that test it; most in 2016 (1)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2021 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses amdizalisib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With LymphomasTerminatedPhase 1HutchmedNCT03786926Written as HMPL-689How we know
- Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular LymphomaCompletedPhase 2Hutchison Medipharma LimitedNCT04849351Written as HMPL-689How we know
- A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory LymphomaCompletedPhase 2HutchmedNCT05713110Written as HMPL-689How we know
- A Study of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or no Standard of Care ExistedCompletedPhase 1Hutchison Medipharma LimitedNCT03128164Written as HMPL-689How we know
- A Study of HMPL-689 in Healthy VolunteersCompletedPhase 1Hutchison Medipharma LimitedNCT02631642Written as HMPL-689How we know
Codes
What other systems call amdizalisib · ClinicalTrials.gg INT016517
- UNII (FDA) F3YMY7783PAMDIZALISIBOne source FDA
- NCI Thesaurus C148532AmdizalisibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | F3YMY7783P | AMDIZALISIB | One source FDA |
| NCI Thesaurus | C148532 | Amdizalisib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.